ANTHROPIC GOES INTO THE DRUG BUSINESS AND BUILDS A LAB TO CURE DISEASES NOBODY ELSE WILL TOUCH Anthropic has launched Claude Science, a full research workbench designed to let scientists discover drugs, analyze genomes, and run biological experiments using AI without switching between a dozen different tools. The platform integrates more than 60 preconfigured tools and connectors, including genomics pipelines, proteomics utilities, and high-performance computing access, into a single environment. It is not a chatbot wrapper. It is a purpose-built scientific interface where the tools themselves, not the chat window, are the primary product. More striking is what Anthropic announced alongside it: an internal drug discovery program targeting neglected diseases. These are illnesses such as rare genetic disorders and tropical diseases that pharmaceutical companies will not develop treatments for because the patient populations are too small or too poor to generate meaningful profit. Anthropic is going to use Claude Science on these diseases itself, generating real scientific results rather than benchmark scores. The strategy is deliberate. Anthropic’s life sciences head Eric Kauderer-Abrams said plainly that to build the right tools to accelerate the industry, Anthropic needs to live it alongside researchers. The company is not pretending to be a pharmaceutical firm. It is using its own product in the hardest scientific settings it can find to prove the tools work, and then selling access to those tools to the biopharma customers who matter. John Jumper, who co-developed AlphaFold at DeepMind and recently joined Anthropic, is central to this effort. Keywords: Claude Science Anthropic, AI drug discovery, Anthropic neglected diseases, biopharma AI 2026